Soligenix - Stock Price History | SNGX

Historical daily share price chart and data for Soligenix since 2021 adjusted for splits. The latest closing stock price for Soligenix as of October 26, 2021 is 0.99.
  • The all-time high Soligenix stock closing price was 4.15 on April 21, 2017.
  • The Soligenix 52-week high stock price is 2.80, which is 182.8% above the current share price.
  • The Soligenix 52-week low stock price is 0.85, which is 14.1% below the current share price.
  • The average Soligenix stock price for the last 52 weeks is 1.40.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Soligenix Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 2.0113 1.4189 3.3400 1.2600 1.2800 -11.72%
2019 0.9450 0.9600 1.4500 0.6701 1.4500 68.60%
2018 1.5534 2.2400 2.4000 0.8500 0.8600 -61.25%
2017 2.3320 2.3700 4.1500 1.8400 2.2195 -1.36%
2016 2.4292 2.3600 2.5500 2.2500 2.2500 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.040B $0.002B
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ? (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86